RMD

AI Research

ResMed Insiders Sell Shares → CEO Farrell $1.25M, Baird Lowers PT to $272, Buy Consensus $296

ResMed saw insider selling activity including CEO Mick Farrell selling approximately $1.25 million in shares, prompting Baird to lower its price target to $272, though the Buy consensus remains intact with an average analyst price target of $296.55 for the sleep apnea device and software leader. The company continues to benefit from GLP-1 weight loss drug tailwinds potentially expanding the diagnosed OSA patient pool. Risks include uncertainty about GLP-1 drugs reducing CPAP therapy adherence over time, competitive pressure from Philips Respironics recovery, and potential reimbursement changes for home sleep devices.